FDA Lifts Clinical Hold on Arbutus's Oral PD-L1 Inhibitor AB-101
ABUS sits 21% above its 52-week low of $3.5.
Summary
The FDA removed the clinical hold on Arbutus's IND for AB-101, an oral PD-L1 inhibitor for chronic hepatitis B, reopening U.S. clinical development. The company has finished Phase 1a/1b work and reported HBsAg decline in two patients, so the safety and early efficacy baseline is already in hand. This clears a regulatory overhang on the program rather than delivering new efficacy data, and Arbutus says it is still evaluating next steps. The 8-K filed this morning confirms the same action. The stock trades near $4.24 with a market cap around $828M after the $230M tender offer retired roughly 23% of shares, so a single early-stage program clearing a hold is meaningful but not thesis-changing on its own. A concrete U.S. trial start with timelines and larger efficacy data would be the next real test.
At the time of this announcement, ABUS was trading at $4.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $828.1M. The 52-week trading range was $3.50 to $5.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.